Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Cost of Revenue (2016 - 2020)

Historic Cost of Revenue for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Q2 2020 value amounting to $3.3 million.

  • Avadel Pharmaceuticals' Cost of Revenue fell 930.43% to $3.3 million in Q2 2020 from the same period last year, while for Mar 2021 it was $3.3 million, marking a year-over-year decrease of 7097.03%. This contributed to the annual value of $5.7 million for FY2020, which is 5264.33% down from last year.
  • Latest data reveals that Avadel Pharmaceuticals reported Cost of Revenue of $3.3 million as of Q2 2020, which was down 930.43% from $2.5 million recorded in Q1 2020.
  • Over the past 5 years, Avadel Pharmaceuticals' Cost of Revenue peaked at $6.6 million during Q1 2018, and registered a low of $2.4 million during Q4 2019.
  • Its 5-year average for Cost of Revenue is $3.6 million, with a median of $3.6 million in 2018.
  • As far as peak fluctuations go, Avadel Pharmaceuticals' Cost of Revenue skyrocketed by 6893.9% in 2018, and later crashed by 5045.51% in 2019.
  • Quarter analysis of 5 years shows Avadel Pharmaceuticals' Cost of Revenue stood at $2.6 million in 2016, then surged by 56.23% to $4.0 million in 2017, then increased by 6.03% to $4.3 million in 2018, then tumbled by 43.76% to $2.4 million in 2019, then surged by 36.08% to $3.3 million in 2020.
  • Its last three reported values are $3.3 million in Q2 2020, $2.5 million for Q1 2020, and $2.4 million during Q4 2019.